Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression. Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
- Conditions
- Obsessive-Compulsive DisorderAnxiety DisordersMental Disorders
- Interventions
- Behavioral: Exposure and Response PreventionDrug: FluoxetineDrug: SertralineDrug: ParoxetineDrug: CitalopramDrug: Fluvoxamine
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Shanghai Mental Health Center
- Target Recruit Count
- 78
- Registration Number
- NCT02022709
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
An Adaptive Treatment Strategy for Adolescent Depression-Continuation
- Conditions
- Adolescent Depression
- Interventions
- Drug: FluoxetineBehavioral: Interpersonal Psychotherapy
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT02017535
- Locations
- 🇺🇸
University of Minnesota, Department of Psychiatry, Minneapolis, Minnesota, United States
A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT01967979
RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke
- Conditions
- Severe Stroke With Affected Arm Motor Function
- Interventions
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2015-01-12
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT01963832
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- University College, London
- Target Recruit Count
- 445
- Registration Number
- NCT01910259
- Locations
- 🇬🇧
Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow, United Kingdom
🇬🇧The Walton Centre, Liverpool, United Kingdom
🇬🇧Derriford Hospital, Plymouth, United Kingdom
Interpersonal Psychotherapy for Treatment Resistant Depression
- Conditions
- Treatment Resistant Depression
- Interventions
- Other: IPT+ antidepressant drugsDrug: fluoxetineDrug: sertralineDrug: paroxetineDrug: CitalopramDrug: escitalopramDrug: fluvoxamineDrug: VenlafaxineDrug: DuloxetineDrug: LithiumDrug: BupropionDrug: RisperidoneDrug: tranylcypromineDrug: ImipramineDrug: amitriptylineDrug: ClomipramineDrug: nortriptylineDrug: trazodoneDrug: MirtazapineDrug: sulpiride
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 74
- Registration Number
- NCT01896349
- Locations
- 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 189
- Registration Number
- NCT01824433
- Locations
- 🇨🇳
Beijing Anding Hospital, Beijing, Beijing, China
A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT01808651
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 513
- Registration Number
- NCT01808612
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
An Adaptive Treatment Strategy for Adolescent Depression
- Conditions
- Adolescent Depression
- Interventions
- Drug: FluoxetineBehavioral: Increased Dose of Interpersonal PsychotherapyBehavioral: Continue to Receive Initial Dose of Interpersonal Psychotherapy
- First Posted Date
- 2013-03-01
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 40
- Registration Number
- NCT01802437
- Locations
- 🇺🇸
University of Minnesota, Department of Psychiatry, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.